secwatch.observer — SEC 8-K summary
======================================

Issuer:     RELMADA THERAPEUTICS, INC. (RLMD)
CIK:        0001553643
Form:       8-K
Filed at:   2023-10-10T23:59:59+00:00
Accession:  0001013762-23-002900
Event type: other
Sentiment:  neutral
Materiality: 0.10
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Relmada Therapeutics updates corporate presentation on CNS pipeline
-------------------------------------------------------------------

- Filed corporate presentation dated October 10, 2023 as Exhibit 99.1.
- No specific financial or clinical data disclosed in the 8-K filing.
- Presentation title: 'Targeting Major Advances in the Treatment of CNS Disorders'.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1553643/000101376223002900/0001013762-23-002900-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1553643/000101376223002900/ea186591-8k_relmada.htm
  HTML page:      https://secwatch.observer/filing/0001013762-23-002900

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer